103 results
8-K
EX-99.1
VTGN
VistaGen Therapeutics Inc
25 Apr 24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
7:18pm
contribute to our confidence in PH15’s potential as an innovative treatment for enhancing psychomotor performance and potentially cognitive impairment … with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain
8-K
EX-99.1
VTGN
VistaGen Therapeutics Inc
1 Apr 24
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder following Positive Results of PALISADE-2
5:25pm
in the second half of this year and advancing our innovative pherine pipeline to deliver pioneering neuroscience to patients affected by mental health … candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms
8-K
EX-99.1
VTGN
VistaGen Therapeutics Inc
13 Feb 24
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
4:33pm
efficacy with a differentiated safety profile. Pherines are investigational neuroactive nasal sprays with innovative proposed mechanisms of action
8-K
EX-99.1
3krrbjc01 dzjbub1k9
3 Jan 24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
5:09pm
8-K
EX-99.1
jhc4mritde6uar09
9 Nov 23
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
4:42pm
8-K
EX-99.2
hcjr 86jlxdu6ipkv7
4 Oct 23
Entry into a Material Definitive Agreement
4:07pm
424B5
60ayg237ssx16 or
3 Oct 23
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
jkxrss wma4k1goq2bp
12 Sep 23
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
8:43pm
8-K
EX-99.1
e3yd47
8 Sep 23
Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese market
5:27pm
8-K
EX-99.1
mz3vg10pl7iyi7b8xoz
22 Aug 23
Vistagen Appoints Cindy Anderson as Chief Financial Officer
8:40am
8-K
EX-99.1
i2ytuje
10 Aug 23
Results of Operations and Financial Condition
4:49pm
8-K
EX-99.1
y45x0p us
28 Jun 23
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
4:28pm
8-K
EX-99.1
kyhxs39s8308wictmb91
23 Jun 23
Other Events
8:35am
8-K
EX-99.1
czhxxowy
21 Jun 23
Other Events
4:43pm